Mark Quick, vice president of corporate development, at Recipharm discusses the key trends influencing CDMO activity and explores what the future has in store for the sector.
For the full article see here
As the industry faces a number of growing pressures, pharmaceutical developers are increasingly partnering with contract development and manufacturing organisations (CDMOs) in order to gain access to expertise and specialist technologies they may not have in-house. The increase in outsourced pharmaceutical manufacturing activity is likely to result in more CDMOs consolidating as they seek to maintain a competitive edge and meet evolving customer demands.
With demand for CDMO services only set to grow in the coming years, the sector will continue to shape itself in order to meet the ever-evolving needs of developers.